6,678 trials
Multiple Sclerosis
Primary: Local Injection Site Reaction (0-6) Scale at Baseline, 2 Weeks — 3.39; 3.47 units on a scale — p=0.45
Bipolar Disorder
Primary: Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores. — 4; 4; 4; 4 participants
Shoulder Pain
Primary: Pectoralis Minor Length After Pectoralis Minor Stretching Protocol — 16.38; 16.87 centimeters — p=<0.05
Myocardial Infarction · Segment Elevation Myocardial Infarction (STEMI)
Primary: Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint) — 143; 145 patients — p=0.8214
Hepatocellular Carcinoma
Primary: Total (Cumulative) Dose Delivery of Sorafenib — 49800; 38000 mg — p=0.0262
Glaucoma
Primary: Diurnal Intraocular Pressure Control — -4.4 millimeters of mercury
Pulmonary Infections · Pseudomonas Aeruginosa in Cystic Fibrosis
Primary: Percentage of Participants With Treatment Emergent Adverse Events, Serious Adverse Events (SAEs) and Deaths — 85.4; 31.2; 0.0 Percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Time to First Moderate or Severe On-treatment COPD Exacerbation — 107.0; 110.0 days — p=0.3497
Fatigue
Primary: Liver Enzymes — 52.1; 59.1; 81.0; 81.6 U/L
Allergic Conjunctivitis
Primary: Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 — 0.23; 0.37 units on a scale
Philadelphia Chromosome Positive · Chronic Myelogenous Leukemia in Chronic Phase
Primary: MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who…
Rheumatoid Arthritis
Primary: Percent Change From Baseline to Week 12 in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic…
13-valent Pneumococcal Vaccine · Premature Birth · Immunization
Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter…
Parkinson Disease
Primary: Change From Baseline (BL) in Unified Parkinson Disease (PD) Rating Scale (UPDRS) Motor Score — -1.91; -1.58; -2.76; -4.31 Score on a scale — p=0.864
Telangiectasis · Spider Veins
Primary: Mean Improvement of Lower Extremity Spider Veins Based on Blinded Photo Assessments — 2.5 points on Improvement scale